# A Long-term Extension Study of Ustekinumab in Pediatric Participants

> **NCT05092269** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 159 (actual)

## Conditions studied

- Crohn Disease
- Colitis, Ulcerative
- Arthritis, Psoriatic

## Interventions

- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT05092269
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-18
- **Primary completion:** 2027-09-29
- **Final completion:** 2028-03-15
- **Target enrollment:** 159 (ACTUAL)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05092269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05092269, "A Long-term Extension Study of Ustekinumab in Pediatric Participants". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05092269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*